Table of contents

Toggle

Newsletter

The TIM Digest: News updates Q2

July, 2025 –

This edition: Where to find us next quarter, a spotlight on our new mucus publication, the FDA’s latest statement on phasing out animal testing, and get to know a new member of the InnoGI family

Q2 was full of energy!  We joined 8 conferences, connected with new and familiar faces, and added 5 new publications featuring the TIM Platform to our growing track record. Plus, we made time for some team fun!

This is your TIM Digest, keeping you up to date on all things TIM and beyond!

• Read  5 new papers featuring TIM^®
• Find out where you can meet the InnoGI team next in the upcoming events of Q3
• Get to know Matthijs Feenstra, our newest addition to commercial team
• Two news highlights: InnoGI in Microbiome Times & a exciting message from the FDA

 

Recent Scientific publication

With the second quarter of 2025 wrapped up, we’re adding another 5 new peer-reviewed studies featuring TIM models! Topics on Food, Probiotics and even a study combining both the TIM-1 and TIM-2 system!

1. Investigation of lipid digestion by fungal and procine lipase supplementation for severe pancreatic insufficiency using TIM
A publication by our own colleague! The tiny-TIM model reveals the efficacy of fungal oral enzymatic supplements in supporting lipid digestion
Garcia et al., 2025 InnoGI Technologies

Keywords: tiny-TIM, Enzymes, Lipid digestion, Supplements, Disease modeling, Comparison, TIM Upper GI

2. Tiny-TIM intestinal fluids vs human intestinal fluids: A comparison of their composition and solubilizing capacity for poorly soluble drugs
tiny-TIM was used to evaluate the solubilizing capacity of its intestinal fluids compared to human intestinal fluids
Goovearts et al., 2025, KU Leuven, Abbvie

Keywords: tiny-TIM, comparison, Food effect, TIM Upper GI

3. Bacillus megaterium DSM 32963 Enhances Specialized Pro-Resolving Mediator Production from an n-3 PUFA Salt in a Dynamic Model of the Human Intestine
A combination of TIM-1 and TIM-2 was used to determine survival of a probiotic strain in the GI tract.
Speckmann et al., 2025, Evonik, University Jena, Maastricht & Wageningen

keywords: TIM-1,TIM-2, Probiotics, Disease modeling, IBD, TIM Upper GI, TIM Colon

4. Synbiotic potential of oat beverage enriched with inulin and fermented by L. rhamnosus LR B in a dynamic in vitro model of human colon
TIM-2 helped research the microbial composition and metabolite production of an oat beverage enriched with probiotics.
Fabiano et al., 2025, University Venlo, University São Paulo

keywords: TIM-2, Food, Probiotic, Prebiotic

5. Specific dietary fibers steer toward distal colonic saccharolytic fermentation using the microbiota of individuals with overweight/obesity
TIM-2 was used as screening tool to (potentially) identify specific fibers based on their SCFA and BCSA production
Van Deuren et al., 2025, University Maastricht, University Wageningen.

Keywords: TIM-2, Food, Dietary Fibers, Protein, Microbial fermentation, TIM Colon

Meet the InnoGI team!

This quarter we we be attending three events! We’re excited to be here with our fresh conference look and The TIM platform!

Meet our team at our booth at CRS or reach out to schedule a meeting during the other events! We are ready to share how TIM is supporting confident, data driven decision making in oral drug and nutrition research. Whether you’re curious about absorption, permeability, or microbiota interactions, we’d love to talk!

Here is were you can find the InnoGI team:

• Controlled Release Society Summit 2025, Booth #303 – July 14-18 ,Philadelphia ,US
• Organ on a Chip & Organoids Event 2025, – August 28th, Utrecht NL
• PharmSci international Conference (APS) – September 9-11, Cardiff UK
• DDF Summit (Drug Delivery & Formulation) US Summit– September 15-16, Boston, US

Attending one of these events?

We’d love to meet for a coffee or chat! Reach out to schedule a meeting!

In case you missed it

Last quarter we released our TIM-2mucus model, in this feature you get to read the results of our validation study and its potential to gut microbiome research. And in case you missed it: The FDA released a statement they are phasing out animal testing, opening the road towards in vitro models such as TIM!

June 04, 2025
FDA is Phasing out animal testing in preclinical safety studies! Opening the road towards new approach methodologies (NAMs) like in vitro models as TIM!

read more!

June 13, 2025
TIM-2muc Validation study reflects in vivo Findings: Results, Data & Graphs and more….

read the full article and learn about TIM-2muc

InnoGI team activity

To wrap up the first quarter, the InnoGI Technologies team took a trip to CORPUS Nederland in Leiden!. The perfect spot for a company doing gastrointestinal (GI) research. If anyone should be traveling through the human body, it’s us, right? We had good laughs, great conversations, and a GI-inspired adventure. It was a fun and fitting way to reflect on all we’ve achieved so far and get energized for upcoming period!

Curious in making this tour through the human body? Visit www.corpusexperience.com

InnoGI introduces….

Get to know InnoGI Each quarter we’ll introduce you to one of our team members. This edition, we welcome our newest team member, Matthijs Feenstra as Sr. Business Development Manager!

Meet Matthijs

I’ve joined InnoGI to strengthen the Business Development team. With over 20 years of experience in various roles within healthcare and the pharmaceutical industry, I look forward to contributing to the continued growth and success of InnoGI, and most importantly, to supporting our clients in meaningful ways.

I’m excited to connect with you, whether that’s at an upcoming event or during a direct conversation. If you see me around, don’t hesitate to say hi, curiosity may not kill the cat, but it might just lead to a great collaboration.

Kind regards,
Matthijs